BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 19879055)

  • 21. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
    Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
    Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
    Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic treatment of malignant pleural mesothelioma.
    Grosso F; Scagliotti GV
    Future Oncol; 2012 Mar; 8(3):293-305. PubMed ID: 22409465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts in chemotherapy for malignant pleural mesothelioma.
    Sørensen JB
    Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant pleural mesothelioma: current treatments and emerging drugs.
    Belli C; Fennell D; Giovannini M; Gaudino G; Mutti L
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):423-37. PubMed ID: 19552609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodality therapy in mesothelioma: role of chemotherapy.
    Vogelzang NJ
    Thorac Surg Clin; 2004 Nov; 14(4):531-42. PubMed ID: 15559060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
    Tomek S; Manegold C
    Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
    Steer J; Bough G; Razak AR; Meachery GJ; Hughes A
    Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant pleural mesothelioma: current concepts in treatment.
    Tsiouris A; Walesby RK
    Nat Clin Pract Oncol; 2007 Jun; 4(6):344-52. PubMed ID: 17534390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.